• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Pasireotide effective in reducing postoperative pancreatic surgery complications

byJon LiuandXu Gao
May 21, 2014
in Chronic Disease, Gastroenterology, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. Pasireotide was effective at reducing the rate of post-pancreatectomy fistulas, leaks and abscesses until 60 days post-op. 

Evidence Rating Level: 1 (Excellent)       

Study Rundown: Postoperative morbidity such as fistulas, leaks and abscesses are common complications after pancreatectomy, affecting 30-50% of patients. Exocrine secretion from remnant pancreatic tissue is thought to contribute towards the development of fistulas and subsequent complications. Somatostain analogues (ie. octreotide) have been used to reduce these secretions.

This phase 3, single-center, randomized, double-blind study evaluated a new somatostatin analogue, pasireotide. Earlier studies have shown that pasireotide has a longer half-life as well as a broader receptor binding profile to somatostatin receptors when compared with octreotide.

In this study, pasireotide achieved the primary endpoint of successfully reducing the rates of fistulas, leaks and abscesses at 60 days post-op. While both pasireotide and placebo groups were well-matched for baseline characteristics, more patients in the pasireotide group did not finish the full course of treatment, thus treatment duration remains unknown. Further limitations include the short follow up time in this study in order to comment on whether the benefits of pasireotide are preserved. Nevertheless, the results of this study show a promising pre- and post-operatively role for pasireotide and future studies will provide more information regarding its long-term safety profile.

Click to read the study, published today in NEJM

RELATED REPORTS

#VisualAbstract: Effect of Hydrocortisone vs Pasireotide on Pancreatic Surgery Complications in Patients With High Risk of Pancreatic Fistula

Effect of Hydrocortisone vs Pasireotide on Pancreatic Surgery Complications in Patients With High Risk of Pancreatic Fistula

2 Minute Medicine Rewind February 10, 2019

Relevant Reading: A Meta-analysis of Outcomes Following Use of Somatostatin and Its Analogues for the Management of Enterocutaneous Fistulas

In-Depth [randomized controlled trial]: This study randomized 300 patients undergoing pancreatectomy (for various indications) into two groups: 900mcg of pasireotide versus placebo given subcutaneously twice daily for 7 days starting on the day of the surgery. The baseline and operative characteristics of both groups were well-matched, however, there was a statistical difference in the number of patients who received all 14 doses (pasireotide v. placebo, 75.7% v. 86.5%, p=0.02) and readmission (pasireotide v. placebo, 17.1% v. 29.1%, p=0.02). The primary endpoint of postoperative fistulas, leaks and abscesses (which required draining) at day 60 was 9.2% versus 20.9%, pasireotide versus placebo respectively (p=0.006). Primary endpoint was also lower for all pasireotide-treated patients in subgroup analysis based on procedure type (pancreaticoduodenectomy, distal pancreatectomy) and technique (dilated duct, nondilated duct). Furthermore, post-hoc analysis demonstrated that patients with surgical drains had a higher risk of reaching the primary end point (drain v. no drain, 25% v. 11%, p=0.003) but the benefits of pasireotide was still preserved in the subgroup of patients with surgical drains (pasireotide v. placebo, 9% v. 44%, p<0.001). Severe adverse events in the pasireotide group included hyperglycemia (50.0%) and nausea/vomiting (2.7%).

More from this author: Idelalisib plus rituximab improves progression-free survival in relapsed CLL, SSRI use during pregnancy not linked to increased risk of autism,Combo antifungal therapy most effective treatment for cryptococcal meningitis 

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: pancreatic surgeryPasireotide
Previous Post

Weight loss during adulthood linked with long-term cardiovascular benefits

Next Post

Oncogenic drivers effective at guiding lung adenocarcinoma therapy

RelatedReports

#VisualAbstract: Effect of Hydrocortisone vs Pasireotide on Pancreatic Surgery Complications in Patients With High Risk of Pancreatic Fistula
StudyGraphics

#VisualAbstract: Effect of Hydrocortisone vs Pasireotide on Pancreatic Surgery Complications in Patients With High Risk of Pancreatic Fistula

March 31, 2020
Rectal indomethacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients
Gastroenterology

Effect of Hydrocortisone vs Pasireotide on Pancreatic Surgery Complications in Patients With High Risk of Pancreatic Fistula

February 21, 2020
Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial
Weekly Rewinds

2 Minute Medicine Rewind February 10, 2019

February 19, 2020
Duloxetine reduces neuropathic pain in chemotherapy patients
Chronic Disease

Longer preoperative treatment of advanced pancreatic cancer may extend survival

December 5, 2013
Next Post
Afatinib shows increased progression-free survival in non-small-cell lung cancer

Oncogenic drivers effective at guiding lung adenocarcinoma therapy

Rhinovirus, genes may interact to increase the risk of childhood asthma

Higher cost-sharing associated with delayed care for children’s asthma

Modulating lymphocyte populations decreases graft rejection in mice

Modulating lymphocyte populations decreases graft rejection in mice

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The Scan by 2 Minute Medicine®: Maternity Leave Left Out, Dry January, A Measles Resurgence, Dr. GPT
  • Former professional football players may be at greater risk of chronic disease
  • Low-dose pirfenidone may be noninferior to standard dosing in patients with idiopathic pulmonary fibrosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options